



Fully Integrated Proton Therapy Software Platform adaPT Treatment Suite Goes Clinical

Cancer patients at Penn Medicine now benefit from the most advanced proton therapy software

Philadelphia, United States, July 3, 2014 – Penn Medicine's Department of Radiation Oncology, the Roberts Proton Therapy Center and IBA (Ion Beam Applications SA) announce that the integrated proton therapy software suite, adaPT Treatment Suite, is now available for clinical use at Penn Medicine.

Penn Medicine has been fully upgraded with the most advanced proton therapy software suite, adaPT Treatment Suite, composed of adaPT Deliver and adaPT Insight*. This modular software platform provides a truly integrated treatment environment for the fastest, safest and most user-friendly proton therapy delivery.



adaPT Deliver is the fully renovated front-end of the treatment delivery. It offers streamlined control of the patient treatment, along with full integration of the Treatment Planning System (TPS) and Oncology Information System (OIS) through DICOM connectivity.

adaPT Deliver provides Penn Medicine among all the other innovative features, the fastest Pencil Beam Scanning, the fastest Room Switching Time and Automatic Beam Operation.



adaPT Insight is the IBA imaging platform, which has been developed in collaboration with the University of Louvain-la-Neuve (UCL). It incorporates image-guidance features such as 3D CBCT** and stereoscopic X-Ray imaging for highly accurate patient treatment, as well as tight integration with adaPT Deliver. An open architecture and programmable workflow configurability builds a solid foundation for the development of future proton specific image-guided solutions.

adaPT Insight is now clinical at Penn Medicine for stereoscopic X-Ray imaging. 3D CBCT is under validation and the first expected clinical use will be in the 2nd half of 2014.

Dr. Alexander Lin, Director of Clinical Operations at Roberts Proton Therapy Center commented: “With adaPT Deliver, our PBS “beam on” time is reduced by 50% and the ultra-fast room switching time ensures that the beam could be shared with no waiting time in our 5-room facility. adaPT Insight provides image registration twice as quickly as our previous platform. The end results significantly benefit the patients, with improved efficiency and throughput, and enhanced accuracy of the proton therapy delivery. We believe that this is another step in improving our ability to helping patients achieve their goals of beating their cancer, and doing so in a way with as few side effects as possible.”



Olivier Legrain, IBA CEO added: “We are delighted to see that adaPT Treatment Suite allows more patients to benefit from Proton Therapy with both faster beam delivery and more accurate patient alignment. At IBA, we are committed to continue to provide the most advanced technologies to our partners and maintain our unrivalled position as an innovator and the world’s leader in the delivery of proton therapy. The fully integrated adaPT Deliver and adaPT Insight platforms constitute major milestones towards our vision of adaptive proton therapy.”

Beth Klein, VP Sales North America for IBA Proton Therapy, shared: “On top of the new centers equipped directly with adaPT Treatment Suite, we have scheduled to deploy it on more than 10 sites of our installed base in the coming two years to leverage the benefit to the patients worldwide and to further enhance the therapist's experience with efficient Proton Therapy delivery.”

** adaPT Insight is the first FDA cleared CBCT software solution in Proton Therapy. adaPT Insight is the brand name of the I2C software suite applicable to the IBA Proton Therapy solutions. (I2C: FDA 510(k) K132847).*

***CBCT is under development. The marketing approval will be subject to review by competent authorities (FDA, Notified bodies, et al...).*

- ENDS -

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide use IBA systems. This includes 17 proton therapy centers in operation and 12 centers under development. Over 25,000 patients have been treated with IBA equipment – more than all competitor installations combined.

About the Penn Medicine’s Department of Radiation Oncology

The Penn Medicine Department of Radiation Oncology is dedicated to providing the highest quality, patient-centered, cancer care, developing new therapies for cancer patients through research, and educating the next generation of outstanding physicians, physicists, and researchers. The Department's Vision and Strategy is to be a global leader in radiation oncology education and research, to set and report national radiation oncology quality and outcomes benchmarks, and to use our network members to increase access to Penn Medicine care closer to patients’ homes.

The Department of Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine and eight community-based network sites delivering more than 66,000 radiation treatments per year. The Department of Radiation Oncology delivers a broad range of radiation therapy services to its



patients, including proton therapy. The Roberts Proton Therapy Center is completely integrated with the Department's conventional radiation therapy services.

Penn Radiation Oncology is not only committed to delivering top-flight radiation therapy, but also to enhancing and improving upon the patient experience by providing a full range of clinical services. An integral component of the Abramson Cancer Center at the University of Pennsylvania, Penn Radiation Oncology can draw upon the center's full resources to deliver the best possible overall care.

Penn Radiation Oncology has a robust research program featuring 11 laboratory investigators and a broad range of clinical and translational research activities. Penn is committed to generating evidence for the use of proton therapy through clinical trials and through developing new biological and physical approaches for improving radiation therapy and bringing these advances to the clinic to benefit patients directly.

The Abramson Cancer Center of the University of Pennsylvania is a world leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute since 1973, one of 41 such Centers in the United States.

www.pennmedicine.org/radiation-oncology/patient-care/treatments/proton-therapy

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
communication@iba-group.com